Author name: Leonardo Arias

EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines

In a Phase 1 study, treatment with Incyte’s KRAS G12D inhibitor in combination with standard-of-care chemotherapy elicited an 89% confirmed objective response rate in patients with a type of pancreatic ductal adenocarcinoma, leading analysts to draw comparisons with Revolution Medicines’ zoldonrasib.

EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines Read More »

Scroll to Top